Laboratory Stock News

Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C. , Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based in-vitro diagnostic (IVD) test cleared by the U.S. Food and Drug Admini...

Test Finder interprets provider questions in context to deliver curated, clinically relevant results, going beyond traditional search Developed in collaboration with Amazon Web Services, Test Finder is now available on Labcorp.com BURLINGTON, N.C. , July 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch o...

First-and-only test of its kind approved under new European Union regulations expands access to personalized cancer care for patients across the EU BURLINGTON, N.C. , July 29, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today PGDx elio™ tissue complete has been CE-marked under the European Union's (EU) new In Vitro Diag...

Labcorp Posts 9.5 Percent Gain in Q2

Labcorp Holdings Inc. (NYSE:LH ) Q2 2025 Earnings Conference Call July 24, 2025 9:00 AM ET Company Participants Adam H. Schechter - President, CEO & Chairman Christin O'Donnell - Vice President of Investor Relations Julia A.

Labcorp raised its annual profit forecast on Thursday after beating Wall Street estimates for second-quarter profit and revenue on robust demand for its diagnostic tests.

Raises Full-Year Guidance Financial results from Operations for second quarter 2025 versus second quarter 2024: Revenue: $3.53 billion versus $3.22 billion Diluted EPS: $2.84 versus $2.43 Adjusted EPS: $4.35 versus $3.94 Raised Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance: Revenue guidance narrowed to 7.5% to 8.6%; midpoint raised by 70 basis points Adjusted EPS range narrowed t...

FRANKLIN, Tenn. & BURLINGTON, N.C.--(BUSINESS WIRE)--Community Health Systems, Inc. (Company) (NYSE: CYH) announced today that its subsidiary, CHS/Community Health Systems, Inc. (CHS), has entered into a definitive agreement with Labcorp (NYSE: LH), pursuant to which Labcorp will acquire select assets and assume certain leases of the ambulatory outreach laboratory services of CHS health systems...